MedWatch

Biogen's US Alzheimer's drug may also come to Europe

An aging population means Aduhelm could also be approved in Europe, Senior Analyst Søren Løntoft Hansen says.

Photo: Ritzau Scanpix/Reuters/Brian Snyder

After being approved by the US Food and Drug Administration (FDA), there is a good chance that Biogen's Alzheimer's drug will also be approved in Europe, Sydbank Senior Analyst Søren Løntoft Hansen says.

The FDA has approved Biogen's Alzeheimer's treatment Aduhelm for use in the US, but it has not been approved in Europe, though there is a good chance this will happen, says Løntoft Hansen.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs